Philippines - English - FDA (Food And Drug Administration)

vizcarra pharmaceutical inc.; distributor: vizcarra pharmaceutical inc. - beroctocog alfa - powder for solution for iv infusion - 1000iu

Philippines - English - FDA (Food And Drug Administration)

vizcarra pharmaceutical inc.; distributor: vizcarra pharmaceutical inc. - beroctocog alfa - powder for solution for iv infusion - 500iu

Canada - English - Health Canada

novo nordisk canada inc - antihemophilic factor viii (recombinant, b-domain truncated), pegylated - powder for solution - 500unit - antihemophilic factor viii (recombinant, b-domain truncated), pegylated 500unit - hemostatics

Canada - English - Health Canada

novo nordisk canada inc - antihemophilic factor viii (recombinant, b-domain truncated), pegylated - powder for solution - 1000unit - antihemophilic factor viii (recombinant, b-domain truncated), pegylated 1000unit - hemostatics

Canada - English - Health Canada

novo nordisk canada inc - antihemophilic factor viii (recombinant, b-domain truncated), pegylated - powder for solution - 1500unit - antihemophilic factor viii (recombinant, b-domain truncated), pegylated 1500unit - hemostatics

Canada - English - Health Canada

novo nordisk canada inc - antihemophilic factor viii (recombinant, b-domain truncated), pegylated - powder for solution - 2000unit - antihemophilic factor viii (recombinant, b-domain truncated), pegylated 2000unit - hemostatics

Canada - English - Health Canada

novo nordisk canada inc - antihemophilic factor viii (recombinant, b-domain truncated), pegylated - powder for solution - 3000unit - antihemophilic factor viii (recombinant, b-domain truncated), pegylated 3000unit - hemostatics

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 1000 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 2000 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 750 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.